AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22217551 — intervention group
Group type: COMPARATOR
Intervention: Conventional examination with white light
Number of subjects: 289
Study 20060162 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mcg sublingual misoprostol
Number of subjects: 809
Study 20060162 — intervention group
Group type: COMPARATOR
Intervention: 40 IU intravenous oxytocin
Number of subjects: 809
Study 17585405 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based nurse and pharmacist active screening team
Number of subjects: 0
Study 16297553 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapezius myalgia (TM)
Number of subjects: 19
Study 16297553 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 19
Study 16297553 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (TM and CON)
Number of subjects: 19
Study 16297553 — intervention group
Group type: EXPERIMENTAL
Intervention: All subjects
Number of subjects: 19
Study 12066254 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypertension (H)
Number of subjects: 29
Study 12066254 — intervention group
Group type: COMPARATOR
Intervention: White-coat hypertension (WH)
Number of subjects: 29
Study 9485240 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower anticoagulation protocol (activated clotting time, > 250 seconds)
Number of subjects: 244
Study 9485240 — intervention group
Group type: COMPARATOR
Intervention: Full anticoagulation protocol (activated clotting time, > 450 seconds)
Number of subjects: 244
Study 8749950 — intervention group
Group type: EXPERIMENTAL
Intervention: CISCA chemotherapy with rhG-CSF (lenograstim) at 2 mg/kg/day subcutaneously on days 3 to 16 (until day 14 for the 14-day interval group)
Number of subjects: 16
Study 8749950 — intervention group
Group type: EXPERIMENTAL
Intervention: CISCA chemotherapy with rhG-CSF
Number of subjects: 16
Study 2611119 — intervention group
Group type: EXPERIMENTAL
Intervention: H2 A + RF alginate antacid (Riflux Forte)
Number of subjects: 2
Study 2611119 — intervention group
Group type: EXPERIMENTAL
Intervention: H2 A + S non‐alginate antacid (Siloxogene)
Number of subjects: 2
Study 30922261 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR)
Number of subjects: 120
Study 30922261 — intervention group
Group type: COMPARATOR
Intervention: Re-trans-catheter arterial chemoembolization (re-TACE)
Number of subjects: 120
Study 30922261 — intervention group
Group type: EXPERIMENTAL
Intervention: SABR
Number of subjects: 120
Study 28375205 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg LSD
Number of subjects: 20
Study 28375205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 25740264 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine supplementation (10 g orally once a day for 3 weeks after initial testing)
Number of subjects: 24
Study 25740264 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine supplementation
Number of subjects: 24
Study 25740264 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 24
Study 24579364 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint heat-sensitive moxibustion
Number of subjects: 144
Study 24579364 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 144
Study 24579364 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication (Sanqi Tongshu capsules)
Number of subjects: 144
Study 20466870 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (0.5 mg once daily for days 1-7, 0.5 mg twice daily for days 8-14, 1 mg twice daily for days 15-21)
Number of subjects: 50
Study 20466870 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (0.5 mg once daily for days 1-14, 0.5 mg twice daily for days 15-21)
Number of subjects: 50
Study 20466870 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (0.5 mg once daily for days 1-14, 1 mg once daily for days 15-21)
Number of subjects: 50
Study 20466870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 18627375 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 3 mg kg(‐1)
Number of subjects: 835
Study 18627375 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg kg(‐1)
Number of subjects: 835
Study 18627375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 835
Study 16618781 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymorphisms in IL-1B, IL-6, IL-8, and IL-10
Number of subjects: 1320
Study 16618781 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplotypes of IL-10 SNPs
Number of subjects: 1320
Study 16618781 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of nonsteroidal anti-inflammatory drugs
Number of subjects: 1320
Study 16618781 — intervention group
Group type: EXPERIMENTAL
Intervention: Early or advanced prostate cancers
Number of subjects: 1320
Study 12456509 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified chemotherapy followed by myeloablative therapy (cyclophosphamide, total body irradiation, and autologous stem cell reinfusion)
Number of subjects: 261
Study 12456509 — intervention group
Group type: COMPARATOR
Intervention: Intensified chemotherapy alone (intermediate-dose melphalan [IDM] without stem cell rescue)
Number of subjects: 261
Study 12456509 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified chemotherapy followed by myeloablative therapy
Number of subjects: 261
Study 12456509 — intervention group
Group type: COMPARATOR
Intervention: Intensified chemotherapy alone
Number of subjects: 261
Study 11197214 — intervention group
Group type: EXPERIMENTAL
Intervention: Am80 therapy
Number of subjects: 24
Study 11197214 — intervention group
Group type: EXPERIMENTAL
Intervention: Am80 therapy with subsequent HLA-matched allogeneic bone marrow transplantation (BMT)
Number of subjects: 24
Study 11197214 — intervention group
Group type: COMPARATOR
Intervention: Am80 therapy without BMT
Number of subjects: 24
Study 11197214 — intervention group
Group type: EXPERIMENTAL
Intervention: PML-RAR alpha fusion transcript undetectable
Number of subjects: 24
Study 8899270 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tetrathiomolybdate (TM) followed by oral zinc (Zn) maintenance therapy
Number of subjects: 14
Study 1379107 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg/day
Number of subjects: 69
Study 1379107 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 10 mg/day
Number of subjects: 69
Study 1379107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 6148164 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (3 micrograms/kg/min)
Number of subjects: 6
Study 6148164 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 6
Study 30660644 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen exposure
Number of subjects: 12
Study 29710212 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase (1.5, 3.0, or 9.0 U per 0.1 mL)
Number of subjects: 9
Study 29710212 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase (9.0 U)
Number of subjects: 9
Study 29710212 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 9
Study 26808629 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (algorithm to prevent cerebral desaturation)
Number of subjects: 201
Study 26808629 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 201
Study 26808629 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 201
Study 26808629 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 201
Study 26808629 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 201
Study 24315720 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 85
Study 24315720 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 85
Study 22137565 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 244
Study 22137565 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 244
Study 22137565 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine
Number of subjects: 244
Study 22137565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study 20646412 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhibitai (480 mg orally twice a day)
Number of subjects: 169
Study 20646412 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (10 mg orally once daily)
Number of subjects: 169
Study 20646412 — intervention group
Group type: COMPARATOR
Intervention: Zhibitai and Atorvastatin (both groups)
Number of subjects: 169
Study 17191187 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1% added to travoprost 0.004%
Number of subjects: 192
Study 17191187 — intervention group
Group type: COMPARATOR
Intervention: Timolol maleate 0.5% added to travoprost 0.004%
Number of subjects: 192
Study 17191187 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1%
Number of subjects: 192
Study 17191187 — intervention group
Group type: COMPARATOR
Intervention: Timolol maleate 0.5%
Number of subjects: 192
Study 14586167 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (400 mg and 600 mg)
Number of subjects: 24
Study 14586167 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (400 mg)
Number of subjects: 24
Study 10889930 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (n = 23)
Number of subjects: 44
Study 10889930 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 21)
Number of subjects: 44
Study 9280995 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone (5 mg methadone/5 ml saline) applied to the dura before the end of surgery
Number of subjects: 40
Study 9280995 — intervention group
Group type: COMPARATOR
Intervention: Saline (5 ml)
Number of subjects: 40
Study 1581081 — intervention group
Group type: EXPERIMENTAL
Intervention: CarboMedics prosthesis
Number of subjects: 141
Study 1581081 — intervention group
Group type: EXPERIMENTAL
Intervention: Björk‐Shiley monostrut prosthesis
Number of subjects: 141
Study 1581081 — intervention group
Group type: EXPERIMENTAL
Intervention: StJude Medical prosthesis
Number of subjects: 141
Study 2997315 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean polysaccharide
Number of subjects: 31
Study 2997315 — intervention group
Group type: COMPARATOR
Intervention: Starch placebo
Number of subjects: 31
Study 2997315 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 31
Study 31809403 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cocaine (10, 20, and 40 mg administered over 2 minutes)
Number of subjects: 0
Study 31809403 — intervention group
Group type: COMPARATOR
Intervention: Single-blind placebo treatment
Number of subjects: 0
Study 29486598 — intervention group
Group type: EXPERIMENTAL
Intervention: New X-ray imaging platform (AlluraClarity) with reduced dose settings
Number of subjects: 41
Study 26644222 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified LNS with milk protein base (54 g/day)
Number of subjects: 213
Study 26644222 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified LNS with soya protein base (54 g/day)
Number of subjects: 213
Study 26644222 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified corn-soya blend (71 g/day)
Number of subjects: 213
Study 26644222 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplement)
Number of subjects: 213
Study 24445981 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloral hydrate (40 mg/kg)
Number of subjects: 90
Study 24445981 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloral hydrate and hydroxyzine (40 mg/kg + 2 mg/kg)
Number of subjects: 90
Study 24445981 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloral hydrate and promethazine (40 mg/kg + 1 mg/kg)
Number of subjects: 90
Study 22259065 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal 17β-estradiol (E2) and progesterone (P) replacement
Number of subjects: 61
Study 22259065 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 61
Study 19926685 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirometry
Number of subjects: 513
Study 17499427 — intervention group
Group type: EXPERIMENTAL
Intervention: HoLEP
Number of subjects: 200
Study 17348236 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyhedron method
Number of subjects: 43
Study 17348236 — intervention group
Group type: COMPARATOR
Intervention: Bisection method
Number of subjects: 43
Study 17348236 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 43
Study 12637460 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (C) 600 mg/m(2) + Doxorubicin (A) 60 mg/m(2)
Number of subjects: 3121
Study 12637460 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (C) 600 mg/m(2) + Doxorubicin (A) 75 mg/m(2)
Number of subjects: 3121
Study 12637460 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (C) 600 mg/m(2) + Doxorubicin (A) 90 mg/m(2)
Number of subjects: 3121
Study 12637460 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (C) + Doxorubicin (A) + Paclitaxel (175 mg/m(2))
Number of subjects: 3121
Study 12637460 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (C) + Doxorubicin (A)
Number of subjects: 3121
Study 10758778 — intervention group
Group type: EXPERIMENTAL
Intervention: Artichoke dry extract (1,800 mg per day)
Number of subjects: 143
Study 10758778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study 8836707 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg a day for 4 days
Number of subjects: 10
Study 8836707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1316058 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomefloxacin 400 mg once daily
Number of subjects: 157
Study 1316058 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin 500 mg every 8 hours
Number of subjects: 157
Study 4077578 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin and iron supplement (twice weekly)
Number of subjects: 40
Study 4077578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 29566406 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 2394
Study 29566406 — intervention group
Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 2394
Study 29566406 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG (tangential clamping)
Number of subjects: 2394
Study 29566406 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG (clampless device)
Number of subjects: 2394
Study 29566406 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG (no aortic manipulation)
Number of subjects: 2394
Study 29566406 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggregate analysis (off-pump CABG)
Number of subjects: 2394
Study 29566406 — intervention group
Group type: COMPARATOR
Intervention: Aggregate analysis (on-pump CABG)
Number of subjects: 2394
Study 27928441 — intervention group
Group type: EXPERIMENTAL
Intervention: Selected exercise program for 24 sessions, 90 minutes per session
Number of subjects: 40
Study 27928441 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study 24866839 — intervention group
Group type: EXPERIMENTAL
Intervention: PARSS intervention group
Number of subjects: 0
Study 24866839 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 21900849 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed bar (410 mg of lignans) for 6 weeks
Number of subjects: 188
Study 21900849 — intervention group
Group type: COMPARATOR
Intervention: Placebo bar for 6 weeks
Number of subjects: 188
Study 21900849 — intervention group
Group type: COMPARATOR
Intervention: Flaxseed bar and Placebo bar
Number of subjects: 188
Study 21900849 — intervention group
Group type: COMPARATOR
Intervention: Placebo bar
Number of subjects: 188
Study 20441245 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl buccal tablet (FBT) 600 microg
Number of subjects: 120
Study 20441245 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl buccal tablet (FBT) 1000 microg
Number of subjects: 120
Study 20441245 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl buccal tablet (FBT) 1200 microg
Number of subjects: 120
Study 20441245 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl buccal tablet (FBT) 1300 microg
Number of subjects: 120
Study 20441245 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone 50 mg
Number of subjects: 120
Study 18827289 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotics
Number of subjects: 0
Study 18827289 — intervention group
Group type: COMPARATOR
Intervention: Perphenazine
Number of subjects: 0
Study 18827289 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0
Study 18827289 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 0
Study 18827289 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 0
Study 18827289 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone and Perphenazine
Number of subjects: 0
Study 16240707 — intervention group
Group type: EXPERIMENTAL
Intervention: Winex (100 mg/5 ml) suspension
Number of subjects: 24
Study 16240707 — intervention group
Group type: COMPARATOR
Intervention: Suprax (100 mg/5 ml) suspension
Number of subjects: 24
Study 11910260 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine maintenance treatment
Number of subjects: 53
Study 11910260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 10331850 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated mobile phone signal at 915 MHz (1 W mean power)
Number of subjects: 36
Study 10331850 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital simulation of mobile phone signal at 915 MHz
Number of subjects: 36
Study 10331850 — intervention group
Group type: COMPARATOR
Intervention: No power (control group)
Number of subjects: 36
Study 8576506 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-medication program (SMP)
Number of subjects: 107
Study 8576506 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 107
Study 1672895 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic carbamazepine (100 and 200 mg tablets)
Number of subjects: 12
Study 1672895 — intervention group
Group type: COMPARATOR
Intervention: Proprietary carbamazepine (Tegretol)
Number of subjects: 12
Study 7019268 — intervention group
Group type: EXPERIMENTAL
Intervention: Hibitane Dental (ICI)
Number of subjects: 13
Study 7019268 — intervention group
Group type: EXPERIMENTAL
Intervention: Plak-Out (Hawe)
Number of subjects: 13
Study 7019268 — intervention group
Group type: COMPARATOR
Intervention: 0.2% aqueous solution of chlorhexidine gluconate
Number of subjects: 13
Study 31194598 — intervention group
Group type: EXPERIMENTAL
Intervention: Six Dried Plums (∼42 g) per day for 2 weeks
Number of subjects: 27
Study 31194598 — intervention group
Group type: COMPARATOR
Intervention: Two Dried Plums (∼14 g) per day for 2 weeks
Number of subjects: 27
Study 28763737 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentional avoidance
Number of subjects: 44
Study 28763737 — intervention group
Group type: COMPARATOR
Intervention: Attentional focusing
Number of subjects: 44
Study 26073878 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoid users
Number of subjects: 6
Study 26073878 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 6
Study 23224687 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol-containing grape extract (8 mg resveratrol)
Number of subjects: 75
Study 23224687 — intervention group
Group type: COMPARATOR
Intervention: Conventional grape extract
Number of subjects: 75
Study 23224687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 21563022 — intervention group
Group type: EXPERIMENTAL
Intervention: Response training (mastication task in response to a visual signal)
Number of subjects: 14
Study 21563022 — intervention group
Group type: COMPARATOR
Intervention: Control group (no response training)
Number of subjects: 14
Study 18474729 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg twice daily)
Number of subjects: 2117
Study 18474729 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium (220 mg twice daily)
Number of subjects: 2117
Study 18474729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2117
Study 17000818 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (0.5 mg) and fentanyl (15 microg)
Number of subjects: 40
Study 17000818 — intervention group
Group type: COMPARATOR
Intervention: Sham intrathecal injection (placebo)
Number of subjects: 40
Study 12562833 — intervention group
Group type: EXPERIMENTAL
Intervention: FAT (50 g/m2)
Number of subjects: 8
Study 12562833 — intervention group
Group type: EXPERIMENTAL
Intervention: GLUCOSE (37.5 g/m2)
Number of subjects: 8
Study 12562833 — intervention group
Group type: EXPERIMENTAL
Intervention: MIXED test (combination of FAT and GLUCOSE)
Number of subjects: 8
Study 12562833 — intervention group
Group type: COMPARATOR
Intervention: WATER
Number of subjects: 8
Study 11878358 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive dissemination (mail-out plus personal contact with midwifery facilitators)
Number of subjects: 23
Study 11878358 — intervention group
Group type: COMPARATOR
Intervention: Simple dissemination (mail-out)
Number of subjects: 23
Study 9013365 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (rapamycin) at dosage levels from 1 mg/m2/day to 13 mg/m2/day
Number of subjects: 40
Study 9013365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 1392995 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole for four weeks plus bismuth 120 mg, tetracycline 500 mg, and metronidazole 400 mg (all four times a day) for the first week (n = 78)
Number of subjects: 155
Study 1392995 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole alone for four weeks (n = 77)
Number of subjects: 155
Study 2865417 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids/calcitonin
Number of subjects: 39
Study 2865417 — intervention group
Group type: EXPERIMENTAL
Intervention: Mithramycin
Number of subjects: 39